News
EPICS Therapeutics Appoints Graeme Fraser PhD, Chief Executive Officer and Raises €12M in Series A Preferred Financing to Advance its Oncology Pipeline
Gosselies, Belgium – October 18th, 2024
EPICS Therapeutics announced today that its Board of Directors has appointed Graeme Fraser, PhD, as the Company’s Chief Executive Officer. He will also join EPICS Therapeutics Board of Directors. Graeme Fraser has been serving as the Company’s Chief Scientific Officer, and further served as the Chief Scientific Officer of OGEDA SA (successful exit to Astellas) since 2007, and therefore has a longstanding relationship with the team at EPICS as well as the Company’s shareholders and Board of Directors. Graeme Fraser will succeed Franz Obermayr, who has decided to step down for personal reasons.
« We thank Franz for his leadership over the past two years and wish him well. During Franz’s tenure, EPICS has progressed well to advance its main asset, EP102, toward entry into clinical development. The Board of Directors looks forward to working with Graeme as EPICS strives to achieve the next, pivotal milestones of executing the clinical development of EP102 in addition to building value in its pipeline of small-molecule candidates engaging novel targets in the treatment of cancer” said Michel Allé, Chairman of the Board of EPICS Therapeutics.
EPICS Therapeutics has also raised €12 Million in Series A preferred financing to fund further developments. Current shareholders of EPICS Therapeutics, including Newton Biocapital, Wallonie Entreprendre (‘WE’), SFPI-FPIM, Fund+ and BNP Paribas Fortis Private Equity have participated in this new round.
« EPICS has invented a quality asset in EP102, a METTL3 inhibitor poised to enter clinical development for the treatment of solid tumors in the novel target space of RNA epigenetics. Furthermore, we have made excellent progress in maturing additional pipeline projects and we anticipate that an additional asset will be nominated for development in 2025. We appreciate the continued confidence from our shareholders as we continue to build value and I am honored to lead the Company at this exciting time,” said Graeme Fraser.
More info: www.epicstherapeutics.com